Related references
Note: Only part of the references are listed.Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
Richard A. Miller et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
mTOR and cancer: many loops in one pathway
Alejo Efeyan et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Rapamycin inhibits multiple stages of c-Neu/ErbB2-induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
Jonathan D. Mosley et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies
T Mathew et al.
CLINICAL TRANSPLANTATION (2004)
Share Paper
